Alps Advisors Inc Ascendis Pharma A/S Transaction History

Alps Advisors Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$84.03 - $110.23 $17,982 - $23,589	-214 Reduced 0.7%	30,416 $3.14 Million
Q2 2022 Aug 11, 2022	BUY	$78.08 - $117.61 $2.39 Million - $3.6 Million	30,630 New	30,630 $2.85 Million
Q2 2019 Aug 07, 2019	SELL	$107.11 - $132.09 $7.55 Million - $9.31 Million	-70,468 Closed	0 $0
Q1 2019 May 01, 2019	SELL	$62.15 - $129.99 $1.66 Million - $3.47 Million	-26,667 Reduced 27.45%	70,468 $8.29 Million
Q4 2018 Feb 04, 2019	BUY	$55.16 - $69.67 $1.75 Million - $2.21 Million	31,687 Added 48.42%	97,135 $6.09 Million
Q3 2018 Oct 25, 2018	BUY	$63.77 - $76.28 $773,147 - $924,818	12,124 Added 22.74%	65,448 $4.64 Million
Q2 2018 Aug 02, 2018	BUY	$58.55 - $73.92 $762,730 - $962,955	13,027 Added 32.33%	53,324 $3.55 Million
Q2 2018 Jul 25, 2018	SELL	$58.55 - $73.92 $496,386 - $626,693	-8,478 Reduced 17.38%	40,297 $1.61 Million
Q1 2018 May 01, 2018	BUY	$38.98 - $68.04 $330,472 - $576,843	8,478 Added 21.04%	48,775 $3.19 Million
Q4 2017 Feb 05, 2018	BUY	$31.98 - $40.38 $267,608 - $337,899	8,368 Added 26.21%	40,297 $1.61 Million
Q3 2017 Nov 03, 2017	BUY	$26.89 - $37.1 $858,570 - $1.18 Million	31,929	31,929 $1.16 Million

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.